First read for a new ticker takes about 20–30 seconds while we build the analysis from the latest fundamentals, estimates, and intelligence. It's saved after this, so future visits are instant.
"The latest data reinforces our belief in the potential of our immuno-oncology therapies."
Moat: Affimed's proprietary technology and strong clinical data provide a competitive advantage in the rapidly evolving immuno-oncology market.
growth - Investors are likely attracted to the potential for high returns from successful drug development.
Moderate - Rising interest rates could increase the cost of capital for funding R&D, impacting future projects and valuations.
Watch on earnings: Clinical trial success rates, Cash runway (months of cash available), Partnership revenue growth.
One Sentence Summary:
Affimed: the setup is constructive — recent data from afm13 trials shows a 60% response rate in patients with relapsed/refractory lymphoma, indicating strong efficacy.
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.